 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...1516171819202122232425...143144» |
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4927;
Further prospective studies are still needed to confirm our conclusions. >
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Elunate (fruquintinib) / Takeda
A phase ?/?a study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: Results of the CEFRU study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4923;
The toxicity was tolerable and no unexpected toxicities were observed (Table 1). Clinical trial information: Clinical trial information: ChiCTR2000038227.
- Perjeta (pertuzumab) / Roche
Incidence of hypomagnesemia in patients with HER2+ breast cancer treated with pertuzumab. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4182;
Our results do not indicate clinical monitoring of hypomagnesemia is necessary for patients receiving P. >* The values were converted into categorical variables (Y/N), since both institutions had different lab reference values.**4th trial date unavailable for 2 patients. One patient received only 3 cycles of P; one patient transferred care elsewhere after 3 cycles of P.
- Libtayo (cemiplimab) / Regeneron, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC). (On Demand | E451; Poster Bd # 11) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3906;
P1
Further evaluation of this regimen is clearly warranted. Clinical trial information: NCT04722523.
- Ibrance (palbociclib) / Pfizer
Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial. (On Demand | E451; Poster Bd # 7) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3901;
P2
The ORR with palbociclib was significantly higher in CDKN2A altered disease. Clinical trial information: NCT03389477.
- NRC-2694 / NATCO
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial. (On Demand | Hall A; Poster Bd # 96b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3883;
P2
The USFDA has approved two ICI agents to treat R/M-HNSCC: pembrolizumab given as monotherapy or with platinum-based chemotherapy for first-line treatment of R/M disease and nivolumab (or pembrolizumab) monotherapy for treatment of disease that progressed on or after platinum-containing chemotherapy...Drugs commonly used in this setting have limited activity and include cetuximab (an epidermal growth factor receptor [EGFR] inhibitor), paclitaxel, docetaxel, a platinum, or 5-fluorouracil...Enrolment to the NAT2694US trial is currently ongoing in USA. Clinical trial information: NCT05283226.
- RP3 / Replimune
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck. (On Demand | Hall A; Poster Bd # 95b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3881;
P2
Clinical trial information: NCT05283226. For recurrent/metastatic (R/M) SCCHN, standard first-line therapy includes immune checkpoint inhibitors (anti
- Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Palbociclib + cetuximab versus cetuximab in patients with CDKN2A-altered, anti-PD-1 resistant, HPV-negative head and neck squamous cell carcinoma (HNSCC): A phase 3 trial. (On Demand | Hall A; Poster Bd # 94a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3878;
P3
0.05. Clinical trial information: NCT04966481.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N). (On Demand | Hall A; Poster Bd # 45) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3829;
P1/2
TMB in tDNA and cfDNA is highly correlated and suggests the possible use as a surrogate marker for tTMB. High TMB in cfDNA derived from ICI-na
- Verzenio (abemaciclib) / Eli Lilly
Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial. (On Demand | Hall A; Poster Bd # 36) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3820;
P2
Abemaciclib had limited antitumor activity in RM-HNSCC harboring molecular alteration in CDK4/6 pathway. Clinical trial information: NCT03356223.
- Gilotrif (afatinib) / Boehringer Ingelheim
Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM). (On Demand | Hall A; Poster Bd # 26) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3810;
P2
Responses were seen in cetuximab pre-treated pts. However, the clinical activity of A in this biomarker-selected population remains limited.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody. (On Demand | Hall A; Poster Bd # 24) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3808;
Although preliminary, these results suggest that this is a promising treatment option for this hitherto untreatable patient group. Further evaluation is warranted.
- Keytruda (pembrolizumab) / Merck (MSD), ImmuFact (eftilagimod alpha) / Immutep
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1. (On Demand | Hall A; Poster Bd # 21) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3805;
P2
TACTI-003 (NCT04811027) a randomized study in 1st line HNSCC is currently recruiting. Response by iRECIST: Clinical trial information: NCT03625323.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. (On Demand | Hall A; Poster Bd # 17) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3801;
P1
The regimen showed preliminary efficacy data in patients with R/M HNSCC, including those with prior CTX resistance. Clinical trial information: NCT03667482.
- Opdivo (nivolumab) / Ono Pharma, BMS
Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial. (On Demand | Hall A; Poster Bd # 15) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3799;
P2
Enrollment to the second stage is ongoing. Clinical trial information: NCT04831320.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C+N). (On Demand | Hall A; Poster Bd # 13) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3797;
P1/2
C+N is associated with a greater reduction in NLR compared to N/P, suggesting that the combination enhances a favorable peripheral immunologic response. Further evaluation is warranted to determine the role of NLR as a biomarker of immunotherapy response.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD). (Live Stream | Hall B1) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3793;
P3
Clinical trial information: NCT01950689. >
- Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001). (Live Stream | Hall B1) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3790;
In this phase 3 multicentric study, triple metronomic chemotherapy as second-line therapy had an overall survival and progression-free survival advantage over NCCN-recommended physician choice therapy. Clinical trial information: CTRI/2021/08/036002.
- SNK01 / NKMAX
The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: Preclinical mouse model and phase I/IIa clinical study. (On Demand | Hall A; Poster Bd # 45) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3466;
P1/2
Clinical trial information: CTRI/2021/08/036002. Background: It is challenging to choose subsequent treatment option in patients with Osimertinib resistance in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)...They received weekly SNK01 in combination with Gemcitabine/Carboplatin (n = 6) or Gemcitabine/Carboplatin/Cetuximab (n = 6), and dose escalation of SNK01 following
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004. (On Demand | Hall A; Poster Bd # 332b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3159;
P2/3
U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG); Pfizer, Eli Lilly; Clinicaltrials.gov ID: NCT05710406. Clinical trial information: NCT05710406.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
The FOxTROT platform: Clinical trials and exploratory research for personalization of neoadjuvant (NA) therapy in locally advanced colon cancer (LACC) (On Demand | Hall A; Poster Bd # 330a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3154;
FOxTROT3 is assessing intensified NAC with modified FOLFOXIRI (mFOLFOXIRI; 5-fluorouracil, oxaliplatin, irinotecan) in fit pts...FOxTROT4: 6 wks NA encorafenib and cetuximab vs 6 wks OxFp NAC...Clinical trial information: ISRCTN83842641. >
- Tukysa (tucatinib) / Seagen, Herceptin (trastuzumab) / Roche
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer. (Available On Demand; Poster Bd # 327b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3149;
P2, P3
Approximately 400 patients will be randomized 1:1 to the TUC experimental arm (TUC [300 mg orally twice daily] + Tras + mFOLFOX) or the SOC arm (mFOLFOX alone or in combination with either bevacizumab or cetuximab)...Enrollment is ongoing in North America, Asia, Australia, and Europe. Clinical trial information: NCT05253651.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) (Available On Demand; Poster Bd # 325b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3145;
P3
bCohort 3 to begin after phase 3 enrollment is complete. cBy BICR.BICR, blinded independent central review; CAPOX, capecitabine/oxaliplatin; FOLFIRI, fluorouracil/leucovorin/irinotecan; FOLFOX, fluorouracil/leucovorin/oxaliplatin; FOLFOXIRI, fluorouracil/leucovorin/oxaliplatin/irinotecan.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) monotherapy in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A secondary endpoint analysis of the ERMES study. (On Demand | Hall A; Poster Bd # 303) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3121;
P3
These data support the hypothesis that ETS might be a clinical dynamic predictor of efficacy of a less intensive maintenance strategy, allowing to plan de-escalation to cet alone after 4 months of FOLFIRI+cet induction. Clinical trial information: NCT02484833.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Upfront vs deferred monoclonal antibodies in metastatic colorectal cancer: A target trial emulation using the GEMCAD 14-01 prospective cohort. (On Demand | Hall A; Poster Bd # 297) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3115;
P=N/A
Our study suggests little or no survival detrimental effect of deferring the use of MAB to the second line of treatment compared with the use of MAB as part of the first line of treatment among pts with mCRC. Clinical trial information: NCT02254941.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer. (On Demand | Hall A; Poster Bd # 296) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3114;
P3
Among Asian patients with BRAF V600E-mutated advanced CRC, the VIC regimen was superior to bevacizumab plus chemotherapy in terms of tumor response and oncological survival, with a tolerable and manageable toxicity profile in the first-line setting. Clinical trial information: NCT05540951.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Overall survival of patients with BRAF-mutant metastatic colorectal cancer treated with encorafenib-cetuximab in a real-world nationwide study in the Netherlands. (On Demand | Hall A; Poster Bd # 289) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3107;
These outcomes should be considered in clinical practice for treatment decision making. Omitting EC for subgroups demonstrating very short OS, such as patients with WHO PS ?2, needs to be considered.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Single nucleotide polymorphisms (SNPs) in MHC class I and II genes to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3, MAVERICC, and TRIBE trials. (Available On Demand; Poster Bd # 278) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3096;
Our results highlight an important role for MHC SNPs as prognostic and predictive biomarkers for first-line treatment in mCRC, with differential effects based on biologic agent and chemotherapy backbone. These biomarkers, when further validated, may contribute to personalized treatment strategies for mCRC patients.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial. (On Demand | Hall A; Poster Bd # 277) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3095;
After neoadjuvant treatment, gain/amplification of MET was associated with a shorter survival with ChemoCetux. By contrast MAPK pathway mutations were largely unchanged supporting earlier findings that alternative resistance mechanisms predominate when EGFRi is combined with chemotherapy.
- Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in patients with metastatic colorectal cancer (mCRC). (Available On Demand; Poster Bd # 276) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3094;
P2
In MSS mCRC, LOH-high was associated with biallelic alterations in the HRR system, worse prognosis and higher benefit from the addition of anti-PDL1 agents to chemotherapy. Considering the low number of LOH-high tumors in our study, these results deserve confirmation in larger cohorts.
- Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO. (On Demand | Hall A; Poster Bd # 275) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3093;
P2
Translational analyses to evaluate the impact of immune-related biomarkers are ongoing. Clinical trial information: NCT04513951.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT). (Available On Demand; Poster Bd # 269) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3088;
pMMR/MSS BRAF V600E mut mCRC patients achieve benefit from TT vs CT independently of RNF43 mutational status, but a higher magnitude of benefit from TT is observed among those with RNF43 mut tumors. These findings deserve confirmation in past and current randomized trials (i.e. BEACON and BREAKWATER).
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAF V600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment. (Available On Demand; Poster Bd # 268) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3087;
An independent cohort of pts treated with second-line chemotherapy +/- antiangiogenic is under investigation as control group. >*for 10% increase.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study. (On Demand | Hall A; Poster Bd # 263) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3082;
P1/2
This study is ongoing to further evaluate the safety and efficacy of D-1533 as monotherapy and in combination with cetuximab or chemotherapy in pts with locally advanced or metastatic CRC. Clinical trial information: NCT04585035.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, ASN007 / Asana BioSci, Erasca, UT MD Anderson Cancer Center, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers). (On Demand | Hall A; Poster Bd # 257) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3076;
P1b/2
The highest dose of ERAS-007 evaluated and cleared by the safety review committee to date is 100 mg BID-QW when combined with EC. Observed PK, toxicity, and preliminary activity support continued evaluation of this combination in pts with BRAF V600E CRC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study). (On Demand | Hall A; Poster Bd # 244) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3065;
These preliminary data suggest a possible prognostic role of TP53 variants in RAS/BRAF wild type mCRC patients receiving first line FOLFIRI/cetuximab followed by Cet alone. Comprehensive genomic profiling is ongoing to identify genomic signatures associated with sensitivity to Cet.
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Consensus molecular subtyping of colorectal cancer to demonstrate cetuximab benefit in right-sided CMS2 tumors, and pembrolizumab benefit in MSS CMS1 tumors. (On Demand | Hall A; Poster Bd # 235) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3056;
A WTS based CMS classifier allows for investigation in a large real-world clinic-genomic database. We found that MSS CMS1 CRC
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC. (Live Stream | Hall D2) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3042;
P3
These patients show outcome characteristics expected for RAS mutant patients (median PFS of 9.0 months and median OS of 22 months). The study thus shows the clinical relevance of liquid biopsy in the verification of RAS mutational status.
- Libtayo (cemiplimab) / Regeneron
Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1. (On Demand | S406; Poster Bd # 282) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2600;
P1
Durable anti-tumor efficacy was observed. mTOR inhibition with prednisone should be the preferred IS regimen when treating KTRs with anti-PD-1 therapy.
- PF-07284892 / Pfizer
A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors. (On Demand | S100bc; Poster Bd # 218) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1881;
P1
This study design enabled combination therapy rescue of disease progression on PF-07284892 monotherapy with 3 pts achieving confirmed PR. Clinical trial information: NCT04800822.
- PF-07799933 / Pfizer
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations. (On Demand | Hall A; Poster Bd # 356b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1863;
P1
The primary objective of Part 3 is efficacy in defined cohorts (total ~120 participants): Cohort 1-2: BRAF V600 mutant melanoma; Cohort 3: BRAF Class II altered melanoma; Cohorts 4-5: BRAF V600 and Class II altered CRC; Cohort 6: other BRAF V600, Class II/III altered solid tumor not qualifying for Cohorts 1-5. Clinical trial information: NCT05355701.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Characterizing the landscape of RING-type E3 ubiquitin transferase-altered (RNF43 alt) colorectal cancer (CRC) and defining unique subsets with potential therapeutic vulnerabilities in microsatellite instability-high (MSI-H) CRC. (On Demand | Hall A; Poster Bd # 332) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1835;
Functional characterization of interplay between the WNT signaling and therapeutically relevant pathways (PI3K/AKT, BRAF, IGF1R, Cetuximab benefit) to better define optimal ICI combination approaches in MSI-H RNF43 alt CRC is ongoing. >*Of tumors with known sidedness, +of tumors with internal IHC.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study. (On Demand | Hall A; Poster Bd # 244) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1747;
These preliminary data suggest that liquid biopsy might better recapitulate the heterogeneity of mCRC and might be useful in clinical practice to complement tissue testing. The clinical relevance of RAS variants detected in cfDNA will be determined in the LIBImAb trial.
- | cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion date, Metastases: Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (clinicaltrials.gov) - Apr 26, 2023
P2, N=96, Active, not recruiting, Sponsor: Washington University School of Medicine
The clinical relevance of RAS variants detected in cfDNA will be determined in the LIBImAb trial. Trial completion date: Dec 2029 --> Dec 2024
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Efficacy and safety of adapalene gel as a reactive treatment for cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck: A historical cohort comparison study. (Pubmed Central) - Apr 25, 2023
Trial completion date: Dec 2029 --> Dec 2024 Adapalene gel may be an effective management option for topical steroid-refractory Cmab-induced skin toxicities and could improve compliance with Cmab therapy.
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Adverse events: #TumorBoardTuesday I just realized....these side effects make this drug sound just like an anti-EGFR monoclonal antibody 😉 👉Sounds alot like what we see with cetuximab (but maybe slightly worse) (Twitter) - Apr 25, 2023
- ||| Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Monotherapy: Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor (clinicaltrials.gov) - Apr 25, 2023
P3, N=81, Recruiting, Sponsor: Washington University School of Medicine
Adapalene gel may be an effective management option for topical steroid-refractory Cmab-induced skin toxicities and could improve compliance with Cmab therapy. Trial completion date: Apr 2025 --> Feb 2027 | Trial primary completion date: Apr 2025 --> Feb 2027
- || garsorasib (D-1553) / InventisBio
Trial completion date, Trial primary completion date, Metastases: KEYNOTE-C15: Study to Evaluate D-1553 in Subjects With Solid Tumors (clinicaltrials.gov) - Apr 25, 2023
P1/2, N=200, Recruiting, Sponsor: InventisBio Co., Ltd
Trial completion date: Apr 2025 --> Feb 2027 | Trial primary completion date: Apr 2025 --> Feb 2027 Trial completion date: Feb 2023 --> Feb 2025 | Trial primary completion date: Nov 2022 --> Nov 2024
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Combination therapy: Pilot Study of Imatinib Cetuximab Combo for H & N Cancer (clinicaltrials.gov) - Apr 25, 2023
P1, N=15, Recruiting, Sponsor: University of Wisconsin, Madison
Trial completion date: Feb 2023 --> Feb 2025 | Trial primary completion date: Nov 2022 --> Nov 2024 Not yet recruiting --> Recruiting
- Comprehensive genomic profiling of tumor tissue and plasma-circulating tumor DNA in RAS/BRAFV600E wild type metastatic colorectal cancer patients: Initial findings from the CAPRI 2-GOIM trial (Auditorium B, Level 0) - Apr 24, 2023 - Abstract #ESMOGI2023ESMO_GI_152;
P2
Both tumor tissue- and liquid biopsy-based comprehensive genomic profiling by NGS identify additional molecular alterations, that could be involved in resistance to anti-EGFR monoclonal antibodies, as compared to PCR-based tumor tissue analysis. CAPRI 2-GOIM trial will determine if NGS would allow better selection of RAS/BRAFV600E WT mCRC patients for the most appropriate treatments through three sequential lines of therapies.